Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29087
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Anders H.-J. | en |
dc.contributor.author | Merkel P.A. | en |
dc.contributor.author | Savage C.O.S. | en |
dc.contributor.author | Specks U. | en |
dc.contributor.author | Kain R. | en |
dc.contributor.author | Jayne D.R. | en |
dc.contributor.author | Lyons P.A. | en |
dc.contributor.author | Gordon J. | en |
dc.contributor.author | Kitching A.R. | en |
dc.contributor.author | Brouwer E. | en |
dc.contributor.author | Basu N. | en |
dc.contributor.author | Kullman J. | en |
dc.date.accessioned | 2021-05-14T09:48:58Z | en |
dc.date.available | 2021-05-14T09:48:58Z | en |
dc.date.copyright | 2020 | en |
dc.date.created | 20200908 | en |
dc.date.issued | 2020-09-08 | en |
dc.identifier.citation | Nature Reviews Disease Primers. 6 (1) (no pagination), 2020. Article Number: 71. Date of Publication: 01 Dec 2020. | en |
dc.identifier.issn | 2056-676X (electronic) | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/29087 | en |
dc.description.abstract | The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of disorders involving severe, systemic, small-vessel vasculitis and are characterized by the development of autoantibodies to the neutrophil proteins leukocyte proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA). The three AAV subgroups, namely granulomatosis with polyangiitis (GPA), microscopic polyangiitis and eosinophilic GPA (EGPA), are defined according to clinical features. However, genetic and other clinical findings suggest that these clinical syndromes may be better classified as PR3-positive AAV (PR3-AAV), MPO-positive AAV (MPO-AAV) and, for EGPA, by the presence or absence of ANCA (ANCA+ or ANCA-, respectively). Although any tissue can be involved in AAV, the upper and lower respiratory tract and kidneys are most commonly and severely affected. AAVs have a complex and unique pathogenesis, with evidence for a loss of tolerance to neutrophil proteins, which leads to ANCA-mediated neutrophil activation, recruitment and injury, with effector T cells also involved. Without therapy, prognosis is poor but treatments, typically immunosuppressants, have improved survival, albeit with considerable morbidity from glucocorticoids and other immunosuppressive medications. Current challenges include improving the measures of disease activity and risk of relapse, uncertainty about optimal therapy duration and a need for targeted therapies with fewer adverse effects. Meeting these challenges requires a more detailed knowledge of the fundamental biology of AAV as well as cooperative international research and clinical trials with meaningful input from patients.Copyright © 2020, Springer Nature Limited. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Nature Research | en |
dc.relation.ispartof | Nature Reviews Disease Primers | - |
dc.subject | infection | en |
dc.subject | kidney disease | en |
dc.subject | macrophage | en |
dc.subject | maintenance therapy | en |
dc.subject | microscopic polyangiitis | en |
dc.subject | monocyte | en |
dc.subject | neutrophil | en |
dc.subject | nonhuman | en |
dc.subject | pathogenesis | en |
dc.subject | pathophysiology | en |
dc.subject | prevalence | en |
dc.subject | priority journal | en |
dc.subject | prognosis | en |
dc.subject | quality of life | en |
dc.subject | respiratory tract disease | en |
dc.subject | review | en |
dc.subject | risk factor | en |
dc.subject | screening | en |
dc.subject | T lymphocyte | en |
dc.subject | treatment duration | en |
dc.subject | Wegener granulomatosis/dt [Drug Therapy] | en |
dc.subject | Wegener granulomatosis/et [Etiology] | en |
dc.subject | autoantigen/ec [Endogenous Compound] | en |
dc.subject | biological marker/ec [Endogenous Compound] | en |
dc.subject | cyclophosphamide/dt [Drug Therapy] | en |
dc.subject | glucocorticoid/dt [Drug Therapy] | en |
dc.subject | immunoglobulin/dt [Drug Therapy] | en |
dc.subject | immunomodulating agent/dt [Drug Therapy] | en |
dc.subject | immunosuppressive agent/dt [Drug Therapy] | en |
dc.subject | mepolizumab/dt [Drug Therapy] | en |
dc.subject | methylprednisolone/dt [Drug Therapy] | en |
dc.subject | neutrophil cytoplasmic antibody/ec [Endogenous Compound] | en |
dc.subject | rituximab/dt [Drug Therapy] | en |
dc.subject | eosinophilic granulomatosis with polyangiitis/dt [Drug Therapy] | en |
dc.subject | microvasculature | en |
dc.subject | *ANCA associated vasculitis/di [Diagnosis] | en |
dc.subject | *ANCA associated vasculitis/dm [Disease Management] | en |
dc.subject | *ANCA associated vasculitis/dt [Drug Therapy] | en |
dc.subject | *ANCA associated vasculitis/ep [Epidemiology] | en |
dc.subject | *ANCA associated vasculitis/et [Etiology] | en |
dc.subject | *ANCA associated vasculitis/pc [Prevention] | en |
dc.subject | B lymphocyte | en |
dc.subject | biopsy | en |
dc.subject | cardiovascular disease | en |
dc.subject | cellular immunity | en |
dc.subject | clinical feature | en |
dc.subject | clinical trial (topic) | en |
dc.subject | comorbidity | en |
dc.subject | complement activation | en |
dc.subject | diagnostic imaging | en |
dc.subject | disease activity | en |
dc.subject | disease association | en |
dc.subject | disease classification | en |
dc.subject | disease severity | en |
dc.subject | environmental factor | en |
dc.subject | genetics | en |
dc.subject | human | en |
dc.subject | incidence | en |
dc.subject.mesh | infection | - |
dc.subject.mesh | kidney disease | - |
dc.subject.mesh | macrophage | - |
dc.subject.mesh | maintenance therapy | - |
dc.subject.mesh | microscopic polyangiitis | - |
dc.subject.mesh | monocyte | - |
dc.subject.mesh | neutrophil | - |
dc.subject.mesh | pathogenesis | - |
dc.subject.mesh | pathophysiology | - |
dc.subject.mesh | quality of life | - |
dc.subject.mesh | respiratory tract disease | - |
dc.subject.mesh | screening | - |
dc.subject.mesh | T lymphocyte | - |
dc.subject.mesh | Wegener granulomatosis | - |
dc.subject.mesh | autoantigen | - |
dc.subject.mesh | biological marker | - |
dc.subject.mesh | cyclophosphamide | - |
dc.subject.mesh | glucocorticoid | - |
dc.subject.mesh | immunoglobulin | - |
dc.subject.mesh | immunomodulating agent | - |
dc.subject.mesh | immunosuppressive agent | - |
dc.subject.mesh | mepolizumab | - |
dc.subject.mesh | methylprednisolone | - |
dc.subject.mesh | neutrophil cytoplasmic antibody | - |
dc.subject.mesh | rituximab | - |
dc.subject.mesh | eosinophilic granulomatosis with polyangiitis | - |
dc.subject.mesh | microvasculature | - |
dc.subject.mesh | ANCA associated vasculitis | - |
dc.subject.mesh | B lymphocyte | - |
dc.subject.mesh | biopsy | - |
dc.subject.mesh | cardiovascular disease | - |
dc.subject.mesh | cellular immunity | - |
dc.subject.mesh | complement activation | - |
dc.subject.mesh | diagnostic imaging | - |
dc.subject.mesh | disease activity | - |
dc.subject.mesh | disease classification | - |
dc.subject.mesh | environmental factor | - |
dc.subject.mesh | genetics | - |
dc.title | ANCA-associated vasculitis. | en |
dc.type | Review | en |
dc.identifier.affiliation | Nephrology | - |
dc.identifier.affiliation | Paediatric - Nephrology | - |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/s41572-020-0204-y | - |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 32855422 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32855422] | en |
dc.identifier.source | 2005992315 | en |
dc.identifier.institution | (Kitching) Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, VIC, Australia (Kitching) Departments of Nephrology and Paediatric Nephrology, Monash Health, Clayton, VIC, Australia (Anders) Renal Division, Medizinische Klinik und Poliklinik IV, LMU Klinikum, Ludwig-Maximilians University, Munich, Germany (Basu) Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom (Brouwer) Vasculitis Expertise Centre Groningen, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands (Gordon) Department of Neuroscience and Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA, United States (Jayne, Lyons) Department of Medicine, University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom (Kullman) Vasculitis Foundation, Kansas City, MO, United States (Lyons) Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom (Merkel) Division of Rheumatology, Department of Medicine and Division of Clinical Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, United States (Savage) Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom (Specks) Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, United States (Kain) Department of Pathology, Medical University Vienna, Vienna, Austria | en |
dc.description.address | A.R. Kitching, Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, VIC, Australia. E-mail: richard.kitching@monash.edu | en |
dc.subject.keyword | disease activity | en |
dc.subject.keyword | disease association | en |
dc.subject.keyword | disease classification | en |
dc.subject.keyword | disease severity | en |
dc.subject.keyword | environmental factor | en |
dc.subject.keyword | genetics | en |
dc.subject.keyword | human | en |
dc.subject.keyword | incidence | en |
dc.subject.keyword | infection | en |
dc.subject.keyword | kidney disease | en |
dc.subject.keyword | macrophage | en |
dc.subject.keyword | maintenance therapy | en |
dc.subject.keyword | microscopic polyangiitis | en |
dc.subject.keyword | microvasculature | en |
dc.subject.keyword | monocyte | en |
dc.subject.keyword | neutrophil | en |
dc.subject.keyword | nonhuman | en |
dc.subject.keyword | pathogenesis | en |
dc.subject.keyword | pathophysiology | en |
dc.subject.keyword | prevalence | en |
dc.subject.keyword | priority journal | en |
dc.subject.keyword | prognosis | en |
dc.subject.keyword | quality of life | en |
dc.subject.keyword | B lymphocyte | en |
dc.subject.keyword | Review | en |
dc.subject.keyword | risk factor | en |
dc.subject.keyword | screening | en |
dc.subject.keyword | T lymphocyte | en |
dc.subject.keyword | treatment duration | en |
dc.subject.keyword | Wegener granulomatosis / drug therapy / etiology | en |
dc.subject.keyword | *ANCA associated vasculitis / *diagnosis / *disease management / *drug therapy / *epidemiology / *etiology / *prevention | en |
dc.subject.keyword | respiratory tract disease | en |
dc.subject.keyword | biopsy | en |
dc.subject.keyword | cardiovascular disease | en |
dc.subject.keyword | cellular immunity | en |
dc.subject.keyword | clinical feature | en |
dc.subject.keyword | clinical trial (topic) | en |
dc.subject.keyword | comorbidity | en |
dc.subject.keyword | complement activation | en |
dc.subject.keyword | diagnostic imaging | en |
dc.relation.libraryurl | LibKey Link | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
dc.identifier.authoremail | Kitching A.R.; richard.kitching@monash.edu | en |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Nephrology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.